ArticleThe Prostate2022
Current and projected number of years of life lost due to prostate cancer: A global study.
Article in The Prostate, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Association of angiotensin-converting enzyme insertion/deletion (ACE I/D) gene polymorphism with susceptibility to prostate cancer: an updated meta-analysis.World journal of surgical oncology · 2022Pooled it
- Effect of high-intensity interval training on aerobic capacity and fatigue among patients with prostate cancer: a meta-analysis.World journal of surgical oncology · 2022Pooled it
- Nitro-Substituted Azo Dyes as Anti-Prostate Cancer Candidates and Nonlinear Optical Properties: Synthesis and In Silico Studies.Journal of fluorescence · 2026Article
- Years of Life Lost in Incidental Prostate Cancer.The Prostate · 2026Article
- A multi-gene urinary extracellular vesicle mRNA panel as a non-invasive biomarkers for prostate cancer detection.Scientific reports · 2026Article
- Innovative dual-mode colorimetric/fluorescent sensors based on transition metal nanozymes: mechanisms, applications, and future perspectives.Mikrochimica acta · 2026Review
- MSI1 Accelerates Prostate Cancer Cell Proliferation, Migration and Glycolysis by Promoting ABHD2 Transcription.Biochemical genetics · 2026Article
- Article
- Mortality and Economic Burden of Prostate Cancer in Bulgaria: Years of Life Lost, Working Years of Life Lost, and Indirect Costs (2008-2023).Epidemiologia (Basel, Switzerland) · 2026Article
- Burden of prostate cancer in older adults, 1990-2021: a systematic analysis based on the global burden of disease study 2021.BMC geriatrics · 2026Article
- Gut Associated Metabolites Enhance PD-L1 Blockade Efficacy in Prostate Cancer.Oncology research · 2026Article
- Does PARP1 up-regulation correlate with PSMA expression in patients with metastatic castration-resistant prostate cancer studied with [European journal of nuclear medicine and molecular imaging · 2026Article
- Effect of neoadjuvant chemotherapy on years of life lost in radical cystectomy-treated T2N0M0 bladder cancer patients.World journal of urology · 2025Article
- In Silico discovery of novel androgen receptor inhibitors for prostate cancer therapy using virtual screening, molecular docking, and molecular dynamics simulations.Scientific reports · 2025Article
- EpiSwitch PSE Blood Test Reduces Unnecessary Prostate Biopsies: A Real-World Clinical Utility Study.Cancers · 2025Article
- Inhibition of Soluble Epoxide Hydrolase Prevents Docetaxel-Induced Painful Peripheral Neuropathy.International journal of molecular sciences · 2025Article
- Use ofWiener klinische Wochenschrift · 2025Article
- Facilitators of, and barriers to, prostate cancer screening uptake: A descriptive phenomenological study of adult men in Namibia.BMC urology · 2025Article
- Normal Weight, Overweight and Obesity Conditions Associated to Prostate Neoplasm Stages-A Systematic Review and Meta-Analysis.Biomedicines · 2025Review
- Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update.European urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundProstate cancer is an important cause of death worldwide. The number of years of life lost (YLL) due to prostate cancer is a metric of the toll of prostate cancer and using projections of demographic changes, can be used to measure future burden.
methodsProstate cancer mortality data by country and world region was retrieved from the Global Cancer Observatory and the World Health Organization mortality data set, and life expectancy was from the United Nations Department of Economic and Social Affairs. We estimated YLL as the difference between age at death in people with prostate cancer and remaining life expectancy for people of the same age in the general population. We also estimated the age-standardized YLL rates per 100,000 males over 50 and the average annual percentage change in YLL rates over the period 2000-2019 and the number of YLL for the year 2040 by applying population projections to the 2020 YLL rates.
resultsIn 2020, 3.5 million person-years of life were lost due to prostate cancer in males over 50, and 40% of YLL were in those aged over 75. Age-standardized rates varied greatly between and within regions. Over the last two decades, rates of YLL have increased in many Asian and African countries while they have decreased in northern American and European countries. Globally, YLL are anticipated to double by 2040 to reach 7.5 million, with the greatest increases in Africa, Asia, and Latin America and the Caribbean.
conclusionThere are wide variations in the burden of prostate cancer globally as measured by YLL. The burden of prostate cancer is projected to increase over time and appears to be highest in Sub-Saharan Africa, Eastern Europe, and Latin America and the Caribbean. It will be critical to plan and implement programs to reduce the burden of prostate cancer globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.